BBR3464

WikiDoc Resources for BBR3464
Articles
Most recent articles on BBR3464 Most cited articles on BBR3464 Review articles on BBR3464 Articles on BBR3464 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on BBR3464 Images of BBR3464 Photos of BBR3464 Podcasts & MP3s on BBR3464 Videos on BBR3464
Evidence Based Medicine
Cochrane Collaboration on BBR3464 Bandolier on BBR3464 TRIP on BBR3464
Clinical Trials
Ongoing Trials on BBR3464 at Clinical Trials.gov Trial results on BBR3464 Clinical Trials on BBR3464 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on BBR3464 NICE Guidance on BBR3464 NHS PRODIGY Guidance FDA on BBR3464 CDC on BBR3464
Books
Books on BBR3464
News
BBR3464 in the news Be alerted to news on BBR3464 News trends on BBR3464
Commentary
Blogs on BBR3464
Definitions
Definitions of BBR3464
Patient Resources / Community
Patient resources on BBR3464 Discussion groups on BBR3464 Patient Handouts on BBR3464 Directions to Hospitals Treating BBR3464 Risk calculators and risk factors for BBR3464
Healthcare Provider Resources
Symptoms of BBR3464 Causes & Risk Factors for BBR3464 Diagnostic studies for BBR3464 Treatment of BBR3464
Continuing Medical Education (CME)
CME Programs on BBR3464
International
BBR3464 en Espanol BBR3464 en Francais
Business
BBR3464 in the Marketplace Patents on BBR3464
Experimental / Informatics
List of terms related to BBR3464

Overview

Skeletal formula of BBR3464

File:Triplatin tetranitrate 3D.png

Space-filling model of BBR3464

BBR3464 (rINN: triplatin tetranitrate) is a new platinum-based cytotoxic drug that is currently undergoing clinical trials throughout the world for the treatment of human cancer. It is a trinuclear platinum coordination complex, with chloride and amine ligands. The drug acts by forming coordinate covalent adducts with cellular DNA, preventing DNA transcription and replication, and through this inducing apoptosis. BBR3464 is structurally similar to, but in a different family from, the anticancer drugs cisplatin, carboplatin and oxaliplatin.

History

BBR3464 was invented by Professor Nicholas Farrell at Virginia Commonwealth University in the United States. The development of this drug came from his earlier work looking at dinuclear platinum derivatives of cisplatin, research he began in the late 1980s. Similar work was also being undertaken by Dr John Broomhead at the Australian National University in Australia. BBR3464 was patented in the mid-1990s and was originally licensed to the pharmaceutical company Roche. In preclinical trials, BBR3464 demonstrated cytotoxic activity in cancer cell lines which have either intrinsic or acquired resistance to cisplatin. On this basis it entered Phase I (Toxicity) clinical trials under the auspices of Novuspharma before the rights were transferred to Cell Therapeutics.

This drug is currently undergoing Phase II (Efficacy) trials with mixed results. So far trials of the drug with patients suffering from ovarian cancer, small cell lung cancer and gastric or gastro-oesophageal adenocarcinomas have been reported in the literature.

Mode of action

The main target of BBR3464 is cellular DNA, similar to cisplatin. Outside of the cell, the concentration of chloride (approx. 100 millimolar) prevents the drugs from hydrolysing, but once inside the cell, where the concentration of chloride drops to between 4 and 20 millimolar, the chloride ligands of BBR3464 come off and the drug is capable of forming coordinate covalent bonds with purine bases on DNA. The novel adducts BBR3464 forms with DNA are though to be the mechanism by which this drug acts; the adducts are able to prevent DNA transcription and replication, thus inducing cell apoptosis.

Side-effects

All platinum based drugs, and particularly BBR3464, cause large dose limiting side-effects. For BBR3464 these are largely diarrhoea, cramps and vomiting, but are so severe that the maximum tolerated dose (MTD) in humans is between 0.9 to 1.1 milligrams per square metre. This is considerably lower than the MTD for all the platinum based drugs currently used in the clinic, like cisplatin (60–120 mg) and carboplatin (approx. 800 mg).

References

• Wheate, Nial J. and Collins, J. Grant (2003). Multi-nuclear platinum complexes as anti-cancer drugs. Coord Chem Rev, 241, 133–145. doi:10.1016/S0010-8545(03)00050-X.

• Wheate, Nial J. and Collins, J. Grant (2005). Multi-nuclear platinum drugs: A new paradigm in chemotherapy. Curr Med Chem Anticancer Agents, 5, 267–279. PMID 15992354.